Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy
Por Laura Sen-Martín, Ángel Fernández-Trasancos, Miguel Á. López-Unzu, Agata Bak, Magdalena Zafra-Castellano, Rajiven Srikantharajah, Divya Pathak, Annika Klotz, Michel N. Kuehn, Alessia Ferrarini, Verónica Labrador-Cantarero, David Sánchez-Ortiz, María Rosaria Pricolo, Natalia Vicente, Diana Velázquez-Carreras, Lucía Sánchez-García, Jon Sicilia, José Ángel Nicolás-Ávila, María Sánchez-Díaz, Saskia Schlossarek, Lorena Cussó, Manuel Desco, María Villalba-Orero, Gabriela Guzmán-Martínez, Enrique Calvo, Roberto Barriales-Villa, Jesús Vázquez, Fátima Sánchez-Cabo, Andrés Hidalgo, Pieter P. de Tombe, Lucie Carrier, James A. Spudich, Kathleen M. Ruppel, Florian Weinberger, Olivier Cazorla, Anthony L. Hessel & Jorge Alegre-Cebollada